|Bid||0.8053 x 3000|
|Ask||0.8500 x 800|
|Day's Range||0.8302 - 0.8500|
|52 Week Range||0.6910 - 7.6000|
|Beta (5Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System ("Orion") at UCLA Medical Center ("UCLA"). The study, which includes four participants at UCLA and two participants at Baylor College of Medicine ("Baylor"), was paused for in-person visits following the guidelines for clinical trials at each institution in March 2020 due to COVID-19. Study visits have now been resumed; several UCLA participants are being examined this week, and Baylor is anticipated to resume its study soon.
BALA CYNWYD, PA / ACCESSWIRE / June 23, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims regarding the following companies for possible breaches of fiduciary ...
Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.